Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).

被引：1
|
作者：
Gaballa, S.
Al-Kali, A.
Kantarjian, H.
Jabbour, E.
Quintas-Cardama, A.
Ayoubi, M.
Borthakur, G.
O'Brien, S. M.
Cortes, J. E.
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6597
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI)
    Nazha, Aziz
    Williams, Loretta A.
    Kantarjian, Hagop M.
    Ault, Patricia S.
    Garcia-Gonzalez, Araceli
    Williams, Janet L.
    Probst, Alexandra
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Shi, Quiling
    Cleeland, Charles S.
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1617 - 1617
  • [22] Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era:: SCT or TKIs?
    Ruiz-Argulles, G. J.
    Tarin-Arzaga, L. C.
    Gonzalez-Carrillo, M. L.
    Gutierrez-Riveroll, K. I.
    Rangel-Malo, R.
    Gutierrez-Aguirre, C. H.
    Cantu-Rodriguez, O. G.
    Gomez-Almaguer, D.
    Giralt, S.
    BONE MARROW TRANSPLANTATION, 2008, 42 (01) : 23 - 28
  • [23] Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    G J Ruiz-Argüelles
    L C Tarin-Arzaga
    M L Gonzalez-Carrillo
    K I Gutierrez-Riveroll
    R Rangel-Malo
    C H Gutiérrez-Aguirre
    O G Cantú-Rodríguez
    D Gómez-Almaguer
    S Giralt
    Bone Marrow Transplantation, 2008, 42 : 23 - 28
  • [24] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
    Abdelall, Waleed
    Kantarjian, Hagop M.
    Devendra, K. C.
    Akosile, Mary
    Borthakur, Gautam
    Verstovsek, Srdan
    Daver, Naval
    Pemmaraju, Naveen
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Ravandi, Farhad
    Konopleva, Marina
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [25] Newer Tyrosine Kinase Inhibitors for CML
    Gupta, Sudeep
    Goyal, Vaibhav
    Telele, Sonali
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2006, 27 (04) : 25 - +
  • [26] Receptor Tyrosine Kinase Inhibitors in Rodent Pulmonary Hypertension
    Moreno-Vinasco, Liliana
    Garcia, Joe G. N.
    MEMBRANE RECEPTORS, CHANNELS AND TRANSPORTERS IN PULMONARY CIRCULATION, 2010, 661 : 419 - 434
  • [27] Pulmonary arterial hypertension induced by tyrosine kinase inhibitors
    Weatherald, Jason
    Chaumais, Marie-Camille
    Montani, David
    CURRENT OPINION IN PULMONARY MEDICINE, 2017, 23 (05) : 392 - 397
  • [28] Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
    El-Dabh, Ashraf
    Acharya, Deepak
    PULMONARY CIRCULATION, 2019, 9 (03)
  • [29] Comparative Analysis of Tyrosine Kinase Inhibitors-Related Pulmonary Hypertension in the Patients Treated By Imatinib, Dasatinib and Nilotinib
    Minami, Mariko
    Miyamoto, Toshihiro
    Arita, Takeshi
    Kamimura, Tomohiko
    Yuda, Junichiro
    Kikushige, Yoshikane
    Mori, Yasuo
    Yoshimoto, Goichi
    Kamezaki, Kenjiro
    Kato, Koji
    Shiratsuchi, Motoaki
    Takenaka, Katsuto
    Iwasaki, Hiromi
    Yamasaki, Satoshi
    Muta, Tsuyoshi
    Tanimoto, Kazuki
    Ogawa, Ryosuke
    Eto, Tetsuya
    Akashi, Koichi
    BLOOD, 2015, 126 (23)
  • [30] EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC)
    Nazha, Aziz
    Jabbour, Elias
    Cortes, Jorge E.
    O'Brien, Susan
    Shan, Jenny
    Garcia-Manero, Guillermo
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1609 - 1609
12345